MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
For further information, please contact:
MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
www.mpxbioceutical.com
Justin Canivet
NATIONAL Equicom
T: +1-416-586-1942
285
Louis Kyron: CCIM David E. Argudo: HC
NOTICE TO READER:
As with all of our Q&A sessions, we were not approached or requested to undertake the Q&A but rather we approach those companies that we feel the timing is right. No compensation of any kind or in any form is every offered, requested, expected, or received.
___________________________________________________________________________________
CIM: Thank you very much for taking a moment to bring our readers up to speed with MPX. There is a lot to take in so I will try to be brief and our readers are encouraged to read the in-depth coverage of MPX inside this issue.
If readers weren’t aware, MPX recently announced a name change from The Canadian Bioceutical Corporation (CSE:BCC). Can you briefly explain the reasons for changing it to our readers?
MPXEF: MPX is focused on becoming a dominant multi-state diversified cannabis company in both the adult use and medical cannabis markets. Our foundation is built on our profitable operations in Arizona, with two and soon to be three, Health For Life Dispensaries and our award-winning Melting Point Extracts (MPX) Brand of concentrates. While we do have some interests in Canada, our focus is really on the U.S. and we wanted our name to reflect our already strong brand presence here and the name change will support the further development of the MPX brand.
CIM: The Cole Memo, which represented a big shift in the federal government to de-prioritize the use of funds to enforce cannabis prohibition under the Controlled Substances Act towards more of a hands-off approach in the United States, was recently reversed by Attorney General Jeff Sessions. Given your strong presence in major U.S. markets where cannabis is legal, what is MPX’s opinion on Attorney General Jeff Session’s ruling on law enforcement in the USA? Do you see any impact on your current operations or future plans?
MPXEF: We are not concerned with the rescinding of the Cole memo, do not believe it will impact MPX negatively and are not altering our business strategy because of it.
We do not expect much to change as a result. We consider it unlikely that federal prosecutors will take much enforcement action in those States where the legalization of cannabis has been implemented.
If there is action taken against those players that are clearly acting outside of State regulations that type of enforcement is a positive for the industry and we welcome it.
Louis Kyron: CCIM David E. Argudo: HC